Quarter Comparison
Revenue
Operating Income
Net Margin
Free Cash Flow
Income Statement
Cash Flow Statement
Balance Sheet
Earnings Release
EX-99.1 2 ibio-20260828xex99d1.htm EX-99.1 Exhibit 99.1 iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update SAN DIEGO, August 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc.
EX-99.1 2 ibio-20260828xex99d1.htm EX-99.1 Exhibit 99.1 iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update SAN DIEGO, August 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced its financial results for the fiscal year ended June 30, 2026, and provided a corporate update on its progress. “Fiscal year 2026 was a transformative year for iBio, most importantly marked by our transition to a clinical-stage company with the initiation of the Phase 1 clinical trial of IBIO-600, a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition,” said Martin Brenner, Ph.D., DVM, Chief Executive Officer and Chief Scientific Officer of iBio. “Add...
Source
Exhibit EX-99.1
0001420720-26-000019
Filed August 28, 2026 at 12:30 PM UTC. The figures above are from the audited statements, not from this release.